# Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)

> **NCT04084080** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **University of Pittsburgh** · enrollment: 173 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **BIOLOGICAL:** Red Blood Cell
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT04084080
- **Lead sponsor:** University of Pittsburgh
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-02-26
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2026-03-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04084080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04084080, "Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT04084080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*